Last Word


Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

SKU: 1056. Category: .

Product Description

The Ariad/Merck deal, valued at almost $1 billion, represents one of the most robust biotech collaborations of its kind and further validates the promise of Ariad’s novel mTOR inhibitor drug deforolimus, which is about to enter the last stage of clinical testing in metastatic soft-tissue and bone sarcomas. Deforolimus also has potential as an anticancer therapy for breast, prostate, and endometrial cancers. Dr. Berger provides his insights on this exciting area of research and what the collaboration means to the company…